Cantor Fitzgerald Reiterates Overweight Rating for uniQure (NASDAQ:QURE)

Cantor Fitzgerald restated their overweight rating on shares of uniQure (NASDAQ:QURE) in a research report report published on Friday, Benzinga reports. The brokerage currently has a $28.00 price objective on the biotechnology company’s stock.

QURE has been the topic of several other reports. The Goldman Sachs Group upped their price objective on shares of uniQure from $6.00 to $10.00 and gave the stock a neutral rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of uniQure to a sell rating in a research report on Monday, August 5th. Finally, HC Wainwright reaffirmed a buy rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $19.40.

uniQure Trading Down 5.8 %

uniQure stock opened at $5.05 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The stock has a market cap of $245.17 million, a P/E ratio of -0.81 and a beta of 0.95. The firm’s fifty day moving average price is $6.68 and its 200-day moving average price is $5.64.

uniQure (NASDAQ:QURE) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. Equities research analysts forecast that uniQure will post -4.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Vestal Point Capital LP bought a new position in shares of uniQure during the 4th quarter valued at $26,572,000. Acadian Asset Management LLC grew its stake in shares of uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the last quarter. Ikarian Capital LLC increased its holdings in shares of uniQure by 198.1% in the first quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock worth $2,439,000 after buying an additional 311,768 shares during the period. Sectoral Asset Management Inc. bought a new stake in shares of uniQure in the 4th quarter valued at about $1,981,000. Finally, Assenagon Asset Management S.A. purchased a new stake in uniQure during the 2nd quarter valued at about $815,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.